effect overlay
activetrials
Active Trials - Other
Huntington's Disease
WAVE 003

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients with Huntington’s Disease
 

HREC: 2020.399
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Anice Abin
Funding: Commercial
Active Trials - Other
Huntington's Disease
Generation HD 2

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Huntington’s Disease
 

HREC: 2023.014
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Anice Abin
Funding: Commercial
Active Trials - Other
NP Disease Type C (NP-C)
NPC Cyclo

A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallelgroup, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1
 

HREC: 2021.078
Principal Investigator: Prof Mark Walterfang
Coordinator contact: Lei Chen
Funding: Commercial
Active Trials - Other
NP Disease Type C (NP-C)
NPC Oral

Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study
 

HREC: 2022.046
Principal Investigator: Prof Mark Walterfang
Coordinator contact: Karen Chidgey
Funding: Commercial
Active Trials - Other
Migraine
RESOLUTION

Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and medication overuse headache
 

HREC: 2022.148
Principal Investigator: Dr Christine Wools
Coordinator contact: Elle Hurley
Funding: Commercial